US Broker Ratings

Alvotech (ALVO) Stock Analysis: Insights on a Healthcare Innovator with 10.57% Potential Upside

Investors with an eye on the healthcare sector might find Alvotech (NASDAQ: ALVO) an intriguing proposition. Based in Luxembourg, this company specializes in developing and manufacturing biosimilar medicines, a segment..

Kymera Therapeutics, Inc. (KYMR) Investor Outlook: Impressive Revenue Growth and Strong Buy Ratings Signal Promising Potential

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a prominent player in the biotechnology sector, has been gaining attention for its innovative approach to drug development. The company specializes in creating small molecule..

MoonLake Immunotherapeutics (MLTX) Investor Outlook: Analyzing a Potential 146.87% Upside in Biotechnology

Investors casting their eyes over the biotechnology sector might want to pay close attention to MoonLake Immunotherapeutics (NASDAQ: MLTX), a Swiss clinical-stage company poised for significant growth. With an average..

ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: A Promising 56.64% Upside in the Biotech Sector

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a key player in the biotechnology sector, is drawing significant attention from investors, particularly due to its potential upside of 56.64%. This San Diego-based company..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Exploring a 47.99% Potential Upside in the Dental Industry

Investors with an eye on the healthcare sector might find DENTSPLY SIRONA Inc. (XRAY) an intriguing prospect, given its prominent presence in the medical instruments and supplies industry. Despite facing..

Belite Bio, Inc (BLTE) Stock Analysis: A 37.94% Potential Upside Amidst Promising Drug Developments

Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical company headquartered in San Diego, California, is drawing significant attention from the investor community. The company, with a market capitalization of $6.68..

Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Exploring a 10.80% Potential Upside

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), a leader in the healthcare sector, particularly within the specialty and generic drug manufacturing industry, has recently caught the attention of investors due to its..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Strong Buy Consensus with a Potential 58% Upside

Privia Health Group, Inc. (NASDAQ: PRVA), a prominent player in the healthcare sector, is garnering significant investor attention with its potential for impressive growth. As a national physician-enablement company based..

Veracyte, Inc. (VCYT) Stock Analysis: A Potential 29% Upside for Investors in the Diagnostics Field

Veracyte, Inc. (VCYT), a prominent player in the healthcare sector, specifically within the diagnostics and research industry, presents a compelling investment opportunity with a potential upside of 29.15%. The company,..

Zai Lab Limited (ZLAB) Stock Analysis: Exploring a 29% Potential Upside Amidst Strong Buy Ratings

Investors looking for opportunities in the biotechnology sector may want to consider Zai Lab Limited (NASDAQ: ZLAB), a Chinese biopharmaceutical company with a market capitalization of $2.88 billion. Despite the..

Viking Therapeutics, Inc. (VKTX) Stock Analysis: Potential Upside of 187% Sparks Investor Interest

Viking Therapeutics, Inc. (NASDAQ: VKTX), a biopharmaceutical company at the forefront of metabolic and endocrine disorder therapies, is capturing attention with a staggering potential upside of 187.06%. The company’s market..

PROCEPT BioRobotics (PRCT) Stock Analysis: Navigating a Promising 25% Upside in the Medical Device Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) stands at the intersection of healthcare innovation and investment potential. With its focus on developing transformative robotic solutions for urology, the company is making strides..

Perrigo Company plc (PRGO) Stock Analysis: Understanding the 7.68% Dividend Yield and Growth Potential

Perrigo Company plc (NYSE: PRGO) presents itself as a significant player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry. Headquartered in Dublin, Ireland, Perrigo offers..

Cytokinetics, Incorporated (CYTK)

⚠️ No article content returned.

..

Oscar Health, Inc. (OSCR) Stock Analysis: Assessing a 19.59% Potential Upside Amid Rapid Revenue Growth

Oscar Health, Inc. (NYSE: OSCR), a prominent player in the healthcare technology sector, has been capturing investor attention with its impressive 70.40% revenue growth and a promising potential upside of..

Vaxcyte, Inc. (PCVX): Investor Outlook with a Potential 93.92% Upside

Vaxcyte, Inc. (NASDAQ: PCVX), a promising player in the biotechnology sector, is capturing the attention of investors with its ambitious vaccine innovation pipeline and substantial potential upside. Currently valued at..

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring an 87.95% Potential Upside

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) stands out in the biotechnology sector with its innovative approach to RNA-targeted medicines. As the company continues to develop groundbreaking treatments, individual investors are keen..

Nuvalent, Inc. (NUVL) Stock Analysis: Navigating the Biotech Landscape with Innovative Cancer Therapies

For investors keeping a keen eye on the healthcare sector, particularly in biotechnology, Nuvalent, Inc. (NASDAQ: NUVL) presents a unique proposition. With a market capitalization of $9.79 billion, this clinical-stage..

Bausch + Lomb Corporation (BLCO) Stock Analysis: Navigating a 12.92% Potential Upside in the Eye Health Industry

Bausch + Lomb Corporation (NYSE: BLCO), a significant player in the healthcare sector, stands out in the medical instruments and supplies industry with its robust presence across the globe. With..

Prestige Consumer Healthcare (PBH) Stock Analysis: Exploring a 45% Potential Upside

Prestige Consumer Healthcare Inc. (NYSE: PBH) has been catching the eye of investors with its solid market presence and significant growth potential. With a market capitalization of $2.21 billion, Prestige..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds